NASDAQ:KZIA Kazia Therapeutics (KZIA) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free KZIA Stock Alerts $0.37 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.36▼$0.3950-Day Range$0.20▼$0.4652-Week Range$0.19▼$1.41Volume54,897 shsAverage Volume725,886 shsMarket Capitalization$6.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Kazia Therapeutics alerts: Email Address Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Kazia Therapeutics Stock (NASDAQ:KZIA)Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.Read More KZIA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KZIA Stock News HeadlinesMarch 20, 2024 | morningstar.comKazia Therapeutics Ltd ADR KZIAMarch 16, 2024 | finance.yahoo.comKZIA Apr 2024 2.500 callApril 27, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 13, 2024 | prnewswire.comKazia announces presentation of new data at AACR Annual MeetingFebruary 21, 2024 | msn.comWhat's Going With Australia-Based Cancer Firm Kazia Therapeutics On Wednesday?February 21, 2024 | finanznachrichten.deKazia Therapeutics Limited: Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointFebruary 21, 2024 | finance.yahoo.comKazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointFebruary 21, 2024 | prnewswire.comKazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointApril 27, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…February 19, 2024 | thestreet.comKazia Therapeutics LimitedFebruary 14, 2024 | wsj.comKazia Therapeutics Ltd. ADRFebruary 13, 2024 | nasdaq.comViking Therapeutics, Inc. Common Stock (VKTX)January 18, 2024 | finance.yahoo.comKAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTSDecember 15, 2023 | msn.comKazia Therapeutics files to sell 591,697 ADSs for holdersDecember 5, 2023 | finance.yahoo.comKazia Therapeutics Announces Closing of $2 Million Registered Direct OfferingDecember 1, 2023 | marketwatch.comKazia Therapeutics Shares Tumble on $2 Million Direct OfferingDecember 1, 2023 | markets.businessinsider.comKazia Therapeutics Announces Registered Direct Offering - Quick FactsDecember 1, 2023 | finance.yahoo.comKazia Therapeutics Announces $2 Million Registered Direct OfferingNovember 29, 2023 | msn.comKazia stock jumps after proposed license deal for paxalisib outside oncologyNovember 29, 2023 | markets.businessinsider.comKazia Therapeutics Enters Non-binding LOI For Paxalisib Rights Outside Of OncologyNovember 29, 2023 | marketwatch.comKazia Therapeutics Signs Letter of Intent for Paxalisib Development, CommercializationNovember 29, 2023 | finance.yahoo.comKAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGYNovember 21, 2023 | finance.yahoo.comKAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETINGNovember 20, 2023 | msn.comKazia Therapeutics gets deficiency notice from NasdaqNovember 18, 2023 | finance.yahoo.comKazia Therapeutics Limited's (NASDAQ:KZIA) large institutional owners must be happy as stock continues to impress, up 28% over the past weekNovember 15, 2023 | finance.yahoo.comKAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETINGNovember 1, 2023 | markets.businessinsider.comKazia Provides Preliminary Update From Phase 2 Study Of Paxalisib In Primary CNS Lymphoma; Stock UpSee More Headlines Receive KZIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KZIA CUSIPN/A CIK1075880 Webwww.kaziatherapeutics.com Phone(129) 472-4101Fax61-2-9476-0388Employees2,021Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick RatioN/A Sales & Book Value Annual Sales$20,000.00 Price / Sales302.29 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book0.74Miscellaneous Outstanding Shares16,340,000Free Float16,178,000Market Cap$6.05 million OptionableOptionable Beta2.12 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. John Edwin Friend II (Age 54)M.D., CEO, MD & Director Comp: $707.94kMs. Gabrielle Heaton BBUS (ACC)CPA, Principal Accounting Officer, VP of Finance & Administration and Principal Financial OfficerMs. Anna SandhamCompany SecretaryKey CompetitorsShuttle PharmaceuticalsNASDAQ:SHPHEnveric BiosciencesNASDAQ:ENVBFirst Wave BioPharmaNASDAQ:FWBIAinosNASDAQ:AIMDiBioNYSE:IBIOView All CompetitorsInstitutional OwnershipPlatinum Investment Management Ltd.Bought 1,821,887 shares on 2/14/2024Ownership: 11.150%Armistice Capital LLCBought 2,475,555 shares on 2/13/2024Ownership: 15.150%View All Institutional Transactions KZIA Stock Analysis - Frequently Asked Questions How have KZIA shares performed in 2024? Kazia Therapeutics' stock was trading at $0.4395 at the beginning of 2024. Since then, KZIA stock has decreased by 15.8% and is now trading at $0.37. View the best growth stocks for 2024 here. Are investors shorting Kazia Therapeutics? Kazia Therapeutics saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 18,400 shares, a drop of 92.9% from the March 31st total of 259,500 shares. Based on an average daily trading volume, of 872,800 shares, the short-interest ratio is presently 0.0 days. View Kazia Therapeutics' Short Interest. What other stocks do shareholders of Kazia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kazia Therapeutics investors own include Fulcrum Therapeutics (FULC), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Idera Pharmaceuticals (IDRA), MEI Pharma (MEIP), Pfizer (PFE), Telesis Bio (TBIO), VYNE Therapeutics (VYNE) and Allena Pharmaceuticals (ALNA). How do I buy shares of Kazia Therapeutics? Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KZIA) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kazia Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
